PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance
Science Advances · 26.05.2023 · 9 (21)
DOI: 10.1126/sciadv.ade4186 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 26.05.2023. Verfasst von Changsheng Huang und 19 weiteren Autor:innen. Beteiligte Einrichtung: GI Cancer Research Institute, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 69-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) or programmed cell death 1 ligand 1 (PD-L1) have enabled some patients with cancer to experience durable, complete treatment responses; however, reliable anti–PD-(L)1 treatment response biomarkers are lacking. Our research found that PD-L1 K162 was methylated by SETD7 and demethylated by LSD2. Furthermore, PD-L1 K162 methylation controlled the PD-1/PD-L1 interaction and obviously enhanced the suppression of T cell activity controlling cancer immune surveillance. We demonstrated that PD-L1 hypermethylation was the key mechanism for anti–PD-L1 therapy resistance, investigated that PD-L1 K162 methylation was a negative predictive marker for anti–PD-1 treatment in patients with non–small cell lung cancer, and showed that the PD-L1 K162 methylation:PD-L1 ratio was a more accurate biomarker for predicting anti–PD-(L)1 therapy sensitivity. These findings provide insights into the regulation of the PD-1/PD-L1 pathway, identify a modification of this critical immune checkpoint, and highlight a predictive biomarker of the response to PD-1/PD-L1 blockade therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- GI Cancer Research Institute, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
- Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China.
- Department of Pathogen Biology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
- Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
- Wuhan Blood Center, Wuhan 430030, China.
- Department of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
ORCID-Profile: Changsheng Huang, Yaqi Chen, Tao Jiang, Panjing Lv, Li Sun, Qian Chu, Keyi Jia, Yan Li, Guihua Wang
Zitieren
APA
Huang, C., Ren, S., Chen, Y., Liu, A., Wu, Q., Jiang, T., Lv, P., Song, D., Hu, F., Lan, J., Sun, L., Zheng, X., Luo, X., Chu, Q., Jia, K., Li, Y., Wang, J., Zou, C., Hu, J., & Wang, G. (2023). PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance. Science Advances, 9(21). https://doi.org/10.1126/sciadv.ade4186
Vancouver
Huang C, Ren S, Chen Y, Liu A, Wu Q, Jiang T, et al. PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance. Science Advances. 2023;9(21). doi:10.1126/sciadv.ade4186
BibTeX
@article{Huang2023,
author = {Huang, Changsheng and Ren, Shengxiang and Chen, Yaqi and Liu, Anyi and Wu, Qi and Jiang, Tao and Lv, Panjing and Song, Da and Hu, Fuqing and Lan, Jingqing and Sun, Li and Zheng, Xue and Luo, Xuelai and Chu, Qian and Jia, Keyi and Li, Yan and Wang, Jun and Zou, Caicun and Hu, Junbo and Wang, Guihua},
title = {PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance},
journal = {Science Advances},
year = {2023},
volume = {9},
number = {21},
doi = {10.1126/sciadv.ade4186}
}
EUVIMED